Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
StemSight raised €2.3M in a funding round led by Voima Ventures to advance stem cell therapy for corneal blindness.
PRIVATEFeb 14, 2025•over 1 year ago
Amount Raised
€2.3 Million
Round Type
Seed
Investors
Business FinlandBiothom OyStephen Industries Inc.Voima Ventures
Description
Tampere-based biotech startup StemSight has raised €2.3 million to advance its stem cell-based therapy for limbal stem cell deficiency. The investment will fund preclinical studies, R&D, and manufacturing pilots to prepare for clinical trials.
Don't miss StemSight's next move
Get an email the moment StemSight raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contactFunding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
StemSight raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.